David E. Hamaoui

Array ( [id] => 12177485 [patent_doc_number] => 20180036421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'METHODS OF MAKING DLL3 ANTIBODY DRUG CONJUGATES' [patent_app_type] => utility [patent_app_number] => 15/694602 [patent_app_country] => US [patent_app_date] => 2017-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 72422 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15694602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13714481 [patent_doc_number] => 20170368195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => ANTI-DLL3 ANTIBODY DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 15/694622 [patent_app_country] => US [patent_app_date] => 2017-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67966 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15694622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16642122 [patent_doc_number] => 10919958 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-16 [patent_title] => Anti-VEGF-A antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/327362 [patent_app_country] => US [patent_app_date] => 2017-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 10542 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16327362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16444907 [patent_doc_number] => 10836819 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-17 [patent_title] => Anti-VEGF-A and anti-ANG2 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/327207 [patent_app_country] => US [patent_app_date] => 2017-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 20 [patent_no_of_words] => 11557 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16327207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12239927 [patent_doc_number] => 20180072790 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'Hemojuvelin Fusion Proteins And Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/681656 [patent_app_country] => US [patent_app_date] => 2017-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 49322 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15681656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16259980 [patent_doc_number] => 10751389 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-25 [patent_title] => Therapeutic use of p75NTR neurotrophin binding protein [patent_app_type] => utility [patent_app_number] => 15/680872 [patent_app_country] => US [patent_app_date] => 2017-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 29 [patent_no_of_words] => 11696 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15680872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12979846 [patent_doc_number] => 20170342153 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => FUSION POLYPEPTIDE INHIBITING VEGF-C, VEGF-D AND/OR ANGIOPOIETIN-2, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/667424 [patent_app_country] => US [patent_app_date] => 2017-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7190 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15667424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14031327 [patent_doc_number] => 10227402 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-12 [patent_title] => Anti-NGF antibodies and anti-NGF antibody fragments [patent_app_type] => utility [patent_app_number] => 15/655478 [patent_app_country] => US [patent_app_date] => 2017-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 98 [patent_figures_cnt] => 102 [patent_no_of_words] => 74104 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15655478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12126276 [patent_doc_number] => 20180009862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-11 [patent_title] => 'MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/644295 [patent_app_country] => US [patent_app_date] => 2017-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 21252 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15644295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17556104 [patent_doc_number] => 11312780 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Antibody directed against the endothelin receptor beta sub-type [patent_app_type] => utility [patent_app_number] => 16/310655 [patent_app_country] => US [patent_app_date] => 2017-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 17 [patent_no_of_words] => 11642 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 347 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16310655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14762091 [patent_doc_number] => 10392430 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-27 [patent_title] => Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic properties [patent_app_type] => utility [patent_app_number] => 15/624845 [patent_app_country] => US [patent_app_date] => 2017-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 67 [patent_no_of_words] => 17498 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15624845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16406763 [patent_doc_number] => 10815306 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-27 [patent_title] => Humanized and chimeric monoclonal antibodies to CD81 [patent_app_type] => utility [patent_app_number] => 16/308113 [patent_app_country] => US [patent_app_date] => 2017-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 10742 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14171733 [patent_doc_number] => 10259862 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-16 [patent_title] => VEGF-binding protein for blockade of angiogenesis [patent_app_type] => utility [patent_app_number] => 15/619917 [patent_app_country] => US [patent_app_date] => 2017-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 13746 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15619917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12247360 [patent_doc_number] => 09920127 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-20 [patent_title] => 'Methods of treating pain with compositions comprising RANK/RANKL antagonists and related compounds' [patent_app_type] => utility [patent_app_number] => 15/619293 [patent_app_country] => US [patent_app_date] => 2017-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 20744 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15619293 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16878051 [patent_doc_number] => 11028184 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => Long-acting PCSK9-specific binding protein and application thereof [patent_app_type] => utility [patent_app_number] => 16/308811 [patent_app_country] => US [patent_app_date] => 2017-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 8558 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16605977 [patent_doc_number] => 10906969 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-02 [patent_title] => Local orbital therapy for thyroid eye disease [patent_app_type] => utility [patent_app_number] => 16/307411 [patent_app_country] => US [patent_app_date] => 2017-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 5 [patent_no_of_words] => 9709 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11969940 [patent_doc_number] => 20170274094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'DLL3 MODULATORS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/616800 [patent_app_country] => US [patent_app_date] => 2017-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 72447 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15616800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12105243 [patent_doc_number] => 09861708 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-09 [patent_title] => 'Kits containing DLL3 antibody drug conjugates' [patent_app_type] => utility [patent_app_number] => 15/616192 [patent_app_country] => US [patent_app_date] => 2017-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 65 [patent_no_of_words] => 72442 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15616192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14342255 [patent_doc_number] => 20190153100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => USE OF ANTI-PD-1 ANTIBODY IN THE TREATMENT OF PATIENTS WITH COLORECTAL CANCER [patent_app_type] => utility [patent_app_number] => 16/306290 [patent_app_country] => US [patent_app_date] => 2017-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16306290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14893983 [patent_doc_number] => 20190290757 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => TREATMENT OF HODGKIN LYMPHOMA USING AN ANTI-PD-1 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/306285 [patent_app_country] => US [patent_app_date] => 2017-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19131 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16306285 [rel_patent_id] =>[rel_patent_doc_number] =>)